Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A vaccine study involving healthy adults

You are invited to take part in a study investigating a new vaccine against Respiratory Syncytial Virus (RSV).  The study is being run by the Oxford Vaccine Group which is part of the University of Oxford.

Please get in touch if you:

·      are aged 18 to 45 years old and in good health

·      are able to attend visits at the Churchill Hospital, Oxford

·      are interested in preventing a major cause of global infant deaths


We will provide reimbursement for your time, inconvenience and travel. The total study participation time is 1 year.


Before you decide whether you would like to take part, it is important for you to understand exactly what the study is about and what participation would involve.  If you would like to read more about the study and see if you are you eligible to take part, please go to here.


If you would like to discuss the study further, please contact us:

Telephone: 01865 857420

Email: info@ovg.ox.ac.uk

Similar stories

Professor Matthew Snape named NIHR Senior Investigator

Awards & Appointments Vaccinology

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

COVID-19 Research Vaccinology

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK

COVID-19 Research Vaccinology

A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Clinical Trials Vaccinology

The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium

COVID-19 Vaccinology

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

COVID-19 Vaccinology

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.